A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502288-40-00

Acronym

MK-1088-002

Enrollment

Registered

2023-02-28

Start date

2022-06-29

Completion date

2023-08-30

Last updated

2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of advanced/metastatic solid tumors

Brief summary

Number of Participants Experiencing Dose-Limiting Toxicities (DLTs), Number of Participants Experiencing Adverse Events (AEs, Number of Participants Discontinuing Study Treatment Due to AEs

Detailed description

Area Under the Plasma Concentration-Time Curve (AUC) of MK-1088, Maximum Plasma Concentration (Cmax) of MK-1088, Minimum Plasma Concentration (Cmin) of MK-1088, Objective Response Rate (ORR)

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs), Number of Participants Experiencing Adverse Events (AEs, Number of Participants Discontinuing Study Treatment Due to AEs	—

Secondary

Measure	Time frame
Area Under the Plasma Concentration-Time Curve (AUC) of MK-1088, Maximum Plasma Concentration (Cmax) of MK-1088, Minimum Plasma Concentration (Cmin) of MK-1088, Objective Response Rate (ORR)	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026